NovoCure (NVCR) Research & Development (2014 - 2026)

NovoCure (NVCR) has reported Research & Development for 13 consecutive years, with $61.7 million the latest figure, recorded in Q2 2026.

• Quarterly Research & Development rose 8.09% year-over-year to $61.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $247.2 million (up 2.98% YoY) and the FY2025 annual result came in at $240.1 million, changed 0.42% from the prior year.
• Research & Development grew to $61.7 million in Q2 2026 per NVCR's latest filing, from $58.4 million in the prior quarter.
• Over the last five years, Research & Development for NVCR reached as high as $68.7 million in Q4 2025 and fell as low as $42.2 million in Q1 2022.
• A 5-year average of $57.7 million and a median of $58.0 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development declined 8.02% — and 2023, when it soared 41.36%.
• Year by year, Research & Development stood at $54.8 million in 2022, then increased by 5.9% to $58.1 million in 2023, then increased by 16.12% to $67.4 million in 2024, then advanced by 1.85% to $68.7 million in 2025, then retreated by 10.16% to $61.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $61.7 million, $58.4 million, and $68.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.